NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

慢性齒齦口腔炎治療藥的全球市場 - 各診斷方法、各治療方法、各終端用戶、各地區:市場規模、佔有率、未來展望、機會分析

Chronic Gingivostomatitis Treatment Market, by Diagnosis, by Treatment, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 979995
出版日期 內容資訊 英文 180 Pages
商品交期: 2-3個工作天內
價格
慢性齒齦口腔炎治療藥的全球市場 - 各診斷方法、各治療方法、各終端用戶、各地區:市場規模、佔有率、未來展望、機會分析 Chronic Gingivostomatitis Treatment Market, by Diagnosis, by Treatment, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年12月18日內容資訊: 英文 180 Pages
簡介

本報告提供全球慢性齒齦口腔炎的治療藥的市場相關分析,疾病和產品概要,市場基本結構及促進、阻礙因素,整體市場規模預測 (以金額為準,過去4年、今後8年份),各診斷/治療方法、各終端用戶、各地區的詳細趨勢,主要企業的簡介、業績、策略計劃等調查。

目錄

第1章 分析目的、前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場力學、規定、趨勢分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 影響度分析
  • 開發平台分析
  • 償付方案
  • 流行病學
  • PEST分析
  • 法規方案
  • 新產品的銷售
  • 合作與契約
  • 市場趨勢

第4章 全球慢性齒齦口腔炎治療藥市場:新型冠狀病毒感染疾病 (COVID-19) 感染擴大的影響

  • COVID-19市場方案
  • COVID-19慢性齒齦口腔炎治療藥市場帶來的影響

第5章 全球慢性齒齦口腔炎治療藥市場:各診斷方法

  • 簡介
  • 體檢
  • 微生物培養
  • 切片檢查
  • 其他

第6章 全球慢性齒齦口腔炎治療藥市場:各治療方法

  • 簡介
  • NSAID (非類固醇消炎劑)
  • 抗病毒藥
  • 抗菌藥
  • 其他

第7章 全球慢性齒齦口腔炎治療藥市場:各終端用戶

  • 簡介
  • 醫院、診所
  • 教育、研究機關
  • 其他

第8章 全球慢性齒齦口腔炎治療藥市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Pfizer Inc.
    • Taj Pharmaceutical limited
    • Ciron pharma
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Merck & CO., Inc.
    • Novartis AG
    • F. Hoffman La Roche AG
    • Eli Lily and Company
    • AstraZeneca Plc.
    • Analyst Views

第10章 附錄

目錄

Title:
Chronic Gingivostomatitis Treatment Market, by Diagnosis (Physical Examination, Microbial Culture, Biopsy, and Others), by Treatment (Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, and Others), by End User (Hospitals & Clinics, Academic & Research, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Gingivostomatitis is a contagious mouth infection, which causes painful sores, blisters, and swelling in the tongue and uvula. It usually spreads through the saliva of an infected individual or by direct contact with a lesion or sore. Gingivostomatitis is also called as herpetic, which is caused by herpes simplex virus and is the most common cause of gingivostomatitis. Gingivostomatitis is the most common among young children, usually under 6 years old, but it may also occur in adults. Geriatric people may experience severe symptoms than adults and children.

Market Dynamics

Rising incidence of gingivostomatitis caused by herpes simplex virus (HSV) is expected to drive the chronic gingivostomatitis treatment market growth. For instance, according to the International Journal of Dentistry, an article published in October 2016, reports that over 90% of gingivostomatitis cases are caused by herpes simplex virus (HSV) type 1 and the remainder are caused by herpes simplex virus (HSV) type 2.

However, lack of identification or diagnosis of chronic gingivostomatitis are expected to hinder the market growth. For instance, according to the Journal of Dental Health Oral Disorders & Therapy, an article published in 2017, states that chronic gingivostomatitis may be asymptomatic in some instances, may be unnoticed in some instances, and sometimes get misdiagnosed with other chronic mouth ulcers.

Key features of the study:

  • This report provides in-depth analysis of the global chronic gingivostomatitis treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic gingivostomatitis treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global chronic gingivostomatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic gingivostomatitis treatment market

Detailed Segmentation:

  • Global Chronic Gingivostomatitis Treatment Market, By Diagnosis:
    • Physical Examination
    • Microbial Culture
    • Biopsy
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By Treatment:
    • Non-steroidal Anti-inflammatory Drugs
    • Antiviral
    • Antibacterial
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By End User:
    • Hospitals & Clinics
    • Academic & Research
    • Others
  • Global Chronic Gingivostomatitis Treatment Market, By Region:
    • North America
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Diagnosis:
      • Physical Examination
      • Microbial Culture
      • Biopsy
      • Others
      • By Treatment:
      • Non-steroidal Anti-inflammatory Drugs
      • Antiviral
      • Antibacterial
      • Others
      • By End User:
      • Hospitals & Clinics
      • Academic & Research
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Taj Pharmaceutical limited.
    • Ciron pharma
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Merck & CO., Inc.
    • Novartis AG
    • F. Hoffman La Roche AG
    • Eli Lily and Company
    • AstraZeneca Plc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Diagnosis
    • Market Snippet, By Treatment
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Chronic Gingivostomatitis Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Chronic Gingivostomatitis Treatment Products

5. Global Chronic Gingivostomatitis Treatment Market, By Diagnosis, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Physical Examination
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Microbial Culture
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Chronic Gingivostomatitis Treatment Market, By Treatment, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Non-steroidal Anti-inflammatory Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Antiviral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Antibacterial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Chronic Gingivostomatitis Treatment Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Academic & Research
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

8. Global Chronic Gingivostomatitis Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Diagnosis, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Taj Pharmaceutical limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ciron pharma
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline PLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & CO., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • F. Hoffman La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lily and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact